HOUSTON INNOVATORS PODCAST EPISODE 202

Houston innovator powers health care innovation by collaboration — inside and outside of the hospital setting

Michelle Stansbury, vice president of innovation and IT applications at Houston Methodist, joins the Houston Innovators Podcast. Photo courtesy of Houston Methodist

It might surprise most to know that Houston Methodist doesn't have an innovation department within their hospital system — at least not one set up as you'd imagine, with a team specifically dedicated to innovation. Instead, Houston Methodist's Digital Innovation Obsessed People, or DIOP, consists of leaders across departments.

Michelle Stansbury is one of those leaders. As vice president of innovation and IT applications at Houston Methodist, she oversees the system's IT department and serves as a leader within its innovation efforts. This includes the Center for Innovation Technology Hub — which opened in 2020 in the Texas Medical Center location and opened its Ion outpost last week.

Stansbury explains on the Houston Innovators Podcast how effective this distribution of innovation responsibilities has been for Houston Methodist. With everyone having a seat at the table — operations knows the biggest problems that need solutions, IT knows how to deploy technology, etc. — implementation of new innovations has been sped up.

"If we partner together, we should be able to succeed fast or fail fast," she says on the show. "We've been able to find a solution, pilot it, and, if it works well, roll it out at a speed that most other organizations have not been able to do. It's been highly successful for us."

The newest way Houston Methodist is mixing up how it brings in innovative solutions to its team and patients is by taking its team outside of the Texas Medical Center and its hospitals in general. Now, Houston Methodist has a permanent tech hub in the Ion, owned and operated by Rice Management Company, on the lower level of the building, completely open to any of the Ion's visitors.

"We've always had a great partnership with Rice. This almost felt like an extension with Houston Methodist and our Rice collaboration with the Ion," Stansbury says. "Our main goals have been how can we utilize the talent that's housed out of that facility."

She explains that the new hub is an extension of the original hub in the TMC hospital, and that innovators who are interested in collaborating with Houston Methodist — especially those with solutions applicable to health care — can visit the Ion hub as an entry point.

Both hub locations showcase pilot technology Houston Methodist is working on, and that technology will then get deployed out into its hospital locations — and especially its Cypress hospital, which is being billed as being the "smart hospital of the future." The construction is underway and expected to deliver in 2025.

Stansbury shares more about this ninth location for Houston Methodist as well as more details on the new tech hub on the podcast. Listen to the interview here — or wherever you stream your podcasts — and subscribe for weekly episodes.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted